DICLOXACILLIN AND FLUCLOXACILLIN INDUCE CYP3A4 AND CYP2C9 IN HUMAN HEPATOCYTES.

被引：0
|
作者：
Stage, T. B. [1 ]
Wong, S. [2 ]
Kroetz, D. L. [1 ]
Khojasteh, C. [2 ]
机构：
[1] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA
[2] Genentech Inc, DMPK, San Francisco, CA 94080 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 101卷 / S1期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PI-107
引用
收藏
页码：S47 / S48
页数：2
相关论文
共 50 条
  • [41] Application of Vivid™ fluorogenic substrates for the in vitro assessment of CYP2C9*1, CYP2C9*2 and CYP2C9*3 metabolism
    Thompson, DV
    Marks, BD
    Goossens, TA
    Trubetskoy, OV
    DRUG METABOLISM REVIEWS, 2002, 34 : 153 - 153
  • [42] Analysis of CYP2C9 promotor variations and possible links to the CYP2C9*2 and CYP2C9*3 exon variants.
    Schubert, C
    Cubic, I
    Kirchheiner, J
    Brockmöller, J
    Roots, I
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (07) : S98 - S98
  • [43] Effects of CYP2C19, CYP2C9 and CYP3A4 gene polymorphisms on plasma voriconazole levels in Chinese pediatric patients
    Fan, Xinghua
    Zhang, Hong
    Wen, Zhipeng
    Zheng, Xiaoli
    Yang, Yi
    Yang, Jihong
    PHARMACOGENETICS AND GENOMICS, 2022, 32 (04): : 152 - 158
  • [44] Exploring the Effect of Compound Glycyrrhizin and Silybinin on the Metabolism of Pexidartinib in Rats Based on CYP3A4 and CYP2C9
    Su, Yanding
    Wei, Xinyi
    Cheng, Qian
    Qi, He
    Chen, Jianghui
    Qiu, Xiang-Jun
    ADVANCES IN PHARMACOLOGICAL AND PHARMACEUTICAL SCIENCES, 2023, 2023
  • [45] In Silico Prediction of Cytochrome P450-Drug Interaction: QSARs for CYP3A4 and CYP2C9
    Nembri, Serena
    Grisoni, Francesca
    Consonni, Viviana
    Todeschini, Roberto
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (06):
  • [46] Interactions of casticin, ipriflavone, and resveratrol with serum albumin and their inhibitory effects on CYP2C9 and CYP3A4 enzymes
    Mohos, Violetta
    Bencsik, Timea
    Boda, Gabriella
    Fliszar-Nyul, Eszter
    Lemli, Beata
    Kunsagi-Mate, Sandor
    Poor, Miklos
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 107 : 777 - 784
  • [47] Implications of In Vitro System Conditions for CYP2C9 and CYP3A4: Impact of pH on Clearance and Enzyme Inhibition
    Rougee, Luc R. A.
    Mohutsky, Michael A.
    Bedwell, David W.
    Ruterbories, Kenneth J.
    Hall, Stephen D.
    FASEB JOURNAL, 2016, 30
  • [48] Suppression of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5 activity by a cocktail of inflammatory cytokines
    Foster, John
    Webber, Guy
    Ormsby, Terry
    Cheung, Yen-Ling
    Paul, Danny S.
    Webber, Colin
    Waring, Adrian
    DRUG METABOLISM REVIEWS, 2016, 48 : 89 - 89
  • [49] The inhibition effect of 20(S)-Protopanaxadiol (PPD) and Ginsenoside Rh2 for CYP2C9 and CYP3A4
    Yao, Yuan
    Han, Wei-wei
    Zhou, Yi-han
    Li, Ze-Sheng
    Li, Qiang
    Li, Xiao-yan
    Chen, Xiao-yan
    Zhong, Da-fang
    POLYMER, 2007, 48 (09) : 2644 - 2648
  • [50] CYP2C9 polymorphisms and CYP2C9*2 genotyping primers
    Goldstein, JA
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (04) : 409 - 410
12345